Search
for
Sort by
Research 481–510 of 499
- Pediatric Ewing's Sarcoma and Permanent Chemotherapy‐Induced Alopecia: A Case–Control Study
- Dermatologic needs of transgender and gender diverse youth: A retrospective cohort study
- Etiology, management, and outcomes of pediatric telogen effluvium: A single‐center study in the United States
- Pathogenesis and clinical features of alopecia in epidermolysis bullosa: A systematic review
- Patient Perspectives: What is alopecia areata?
- A patient with Cronkhite-Canada syndrome whose entire digestive tracts was examined endoscopically
- A child with generalized hypertrichosis due to secondary topical minoxidil exposure
- 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration
- Minoxidil
- The treatment of alopecia areata.
- Nevus lipomatosus cutaneous superficialis with perifollicular fibrosis.
- Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
- Multi-scale modeling for cell fate specification during regeneration and development
- Effect of antioxidants in protecting chemically damaged hair
- Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review
- Experience of using improved formula of topical tretinoin in patients with acne
- FDA approves label addition for PDE-5 inhibitor
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
- Organic Causes of Erectile Dysfunction in Men Under 40
- Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia
- Adverse effects of common medications on male fertility
- Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis